. 2012 Sep 13;22(4):554–566. doi: 10.1089/scd.2011.0709

Table 3.

In Vivo Tumorigenicity and Treatment (Side Population and Nonside Population Cells of GBC-SD)

Group	Volume D0 (mm³)	Volume D2 (mm³)	Volume D4 (mm³)	Volume D6 (mm³)	Volume D8 (mm³)
SP (GBC-SD)
Con	0.101±0.011	0.139±0.013	0.199±0.022	0.277±0.021	0.379±0.025
CDDP	0.101±0.012	0.123±0.012	0.174±0.021	0.212±0.02	0.301±0.049
Emodin	0.102±0.074	0.108±0.098	0.142±0.015^a	0.183±0.029^a	0.258±0.036^a
CDDP+emodin	0.103±0.01	0.092±0.011^a	0.084±0.01^a	0.078±0.011^a	0.074±0.009^a
Non-SP (GBC-SD)
Con	0.102±0.008	0.121±0.017	0.17±0.025	0.232±0.037	0.312±0.04
CDDP	0.102±0.008	0.103±0.008^a	0.136±0.028^a	0.181±0.022^a	0.25±0.028^a
Emodin	0.102±0.01	0.12±0.019	0.169±0.014	0.221±0.017	0.309±0.027
CDDP+emodin	0.1±0.007	0.093±0.002^a	0.084±0.005^a	0.074±0.005^a	0.07±0.005^a

^{^a}

P<0.05, experimental group compared with the control group.

Emodin sensitizes SP and non-SP cells of GBC-SD to CDDP cytotoxicity in xenograft tumors. D, day; (n=6).